@article{oai:nagasaki-u.repo.nii.ac.jp:00002100,
 author = {Takaki, Masahiro and Tanaka, Takeshi and Komohara, Yoshihiro and Tsuchihashi, Yoshiko and Mori, Daisuke and Hayashi, Kentaro and Fukuoka, Junya and Yamasaki, Naoya and Nagayasu, Takeshi and Ariyoshi, Koya and Morimoto, Konosuke and Nakata, Koh},
 journal = {Respiratory Medicine Case Reports},
 month = {Aug},
 note = {Hereditary pulmonary alveolar proteinosis (PAP) caused by mutations in CSF2RA or CSF2RB, which encode GM-CSF receptor α and β respectively, is a rare disease. Although some experimental therapeutic strategies have been proposed, no clinical evidence has yet been reported. We herein describe the clinical course and recurrence of hereditary PAP after lung transplantation. A 36-year-old woman developed PAP of unknown etiology. She underwent bilateral lung transplantation from living donors at the age of 42 years because of severe respiratory failure complicated by pulmonary fibrosis. However, PAP recurred after 9 months, and we found that donor-origin alveolar macrophages had been almost completely replaced with recipient-origin macrophages. We performed a genetic analysis and identified a point deletion in the CSF2RB gene that caused a GM-CSF receptor-mediated signaling defect. PAP progressed with fibrosis in both transplanted lungs, and the patient died of respiratory failure 5 years after the lung transplantation. Distinct from recent reports on pulmonary macrophage transplantation in mice, this case suggests that human alveolar macrophages might not maintain their population only by self-renewal but may depend on a supply of precursor cells from the circulation. Bone marrow transplantation should be considered for treatment of severe PAP with GM-CSF receptor gene deficiency., Respiratory Medicine Case Reports, 19, pp.89-93; 2016},
 pages = {89--93},
 title = {Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB},
 volume = {19},
 year = {2016}
}